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Recent developments in electron microscopy (EM) have led to a step change in
our ability to solve the structures of previously intractable systems, especially
membrane proteins and large protein complexes. This has provided new
opportunities in the field of structure-based drug design, with a number of high-
profile publications resolving the binding sites of small molecules and peptide
inhibitors. There are a number of advantages of EM over the more traditional
X-ray crystallographic approach, such as resolving different conformational
states and permitting the dynamics of a system to be better resolved when not
constrained by a crystal lattice. There are still significant challenges to be
overcome using an EM approach, not least the speed of structure determination,
difficulties with low-occupancy ligands and the modest resolution that is
available. However, with the anticipated developments in the field of EM, the
potential of EM to become a key tool for structure-based drug design, often
complementing X-ray and NMR studies, seems promising.
1. Introduction
The world is in constant need of new therapeutics to treat a
range of pathogens and disorders such as infectious diseases,
cancer and Alzheimer’s. However, the process of drug
discovery can be slow and fraught with numerous hurdles and
unforeseen difficulties. From the discovery of the initial ‘hit’
compound, the time taken for a compound to reach the clinic
is over ten years, owing to the processes involved in clinical
testing and target validation. This highlights the enormous
amount of compound development, staff and research hours
dedicated to turning the initial hit compound into a drug
candidate. Structural information can provide two important
strands of information: the first is target validation and the
second is in discovering new lead compounds and improving
selectivity. Common approaches to drug discovery include
high-throughput screening (HTS), structure-based design
(SBD) and fragment-based drug design (FBDD).
HTS is an automated process that allows large multimillion-
compound libraries to be screened against a biological target.
It has been the mainstay for lead identification in the phar-
maceutical industry for the past two decades (Pereira &
Williams, 2007; Macarron et al., 2011). Typically, 10 000
compounds are screened per day to identify hits that show a
therapeutic response, with hit compounds being progressed
into hit-to-lead development. Structure–activity relationships
(SAR) can then lead to improved potency and selectivity of
the compound series by developing a balanced profile of
physicochemical properties. Despite the low probability of
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identifying a hit, this approach has been successful in
numerous drug-discovery programs (Macarron et al., 2011),
including those for the antiretroviral inhibitor maraviroc and
the protease inhibitor tipranavir, which are used to treat HIV
infection, and the antihyperglycaemia inhibitor sitagliptin,
which is used to treat type 2 diabetes.
However, there are limitations to the efficacy and effec-
tiveness of HTS (Paul et al., 2010; Bakken et al., 2012),
not least the large chemical libraries needed (>1 million
compounds), which can represent a challenge to academic
research groups or small biotech companies. Moreover, the
maintenance and quality control of these libraries requires
sufficient time and resources. Library compounds may also
have poor physicochemical properties, such as low solubility,
or functional groups associated with ‘frequent hitter’ beha-
viour, which results in a high percentage of false-positive
results (McGovern et al., 2002; Irwin et al., 2015). These large
libraries cover only a small fraction of chemical space, which
may hinder the discovery of inhibitors for targets with unusual
binding sites such as allosteric sites or protein–protein inter-
actions (PPIs). To reduce the cost of HTS, new strategies
involving smaller numbers of diverse compounds are being
sought (Crisman et al., 2007; Zhu et al., 2013; Nissink et al.,
2014).
Structure-based design (SBD) utilizes prior structural
knowledge of the target system to design new inhibitors and
can be used to complement HTS methods via the structural
development of an HTS ‘hit’, or as an independent approach
such as identifying new leads viamolecular docking or de novo
design. Molecular docking, or more commonly virtual high-
throughput screening (vHTS), can be used to computationally
screen libraries of compounds from databases, such as
ZINC15 (Sterling & Irwin, 2015), against the desired target
and identifies compounds which are predicted to bind with
high affinity (Rognan, 2013). Structure-based design has
played a pivotal role in the discovery of close to 20 drugs in
clinical use (Irwin & Shoichet, 2016), with the most well
documented examples including the peptidomimetic HIV
protease inhibitors nelfinavir, amprenavir and lopinavir.
Fragment-based drug discovery (FBDD) combines elements
of both SBD and HTS, and has gained significant momentum
as a drug-discovery platform in the last 20 years (Zartler, 2014;
Erlanson et al., 2016). Fragments are of lower molecular
weight (<300 Da) and lipophilicity (<3) than drug-like mole-
cules and are usually defined as having less than 20 heavy
atoms. Fragment libraries consist of a few thousand molecules,
thus being several orders of magnitude smaller than HTS
collections, and the sampling of chemical space is more effi-
cient (Erlanson et al., 2016). Two FDA-approved drugs, the
BRAF kinase inhibitor vemurafenib (Bollag et al., 2012) and
the BCL-2 inhibitor venetoclax (Souers et al., 2013), are
examples of oncology drugs discovered using FBDD.
While X-ray crystallography has provided a wealth of
structural information for structure-based discovery pipelines,
there are a number of limitations. These include difficulties
in obtaining high-quality crystals of the protein of interest
(Niedzialkowska et al., 2016), crystal-packing artefacts in the
structure and trapping only a static snapshot of the protein–
inhibitor complex (Steuber et al., 2006; Davis et al., 2008).
These problems, in particular the generation of high-quality
crystals, have a significant impact in the membrane-protein
field. For example, despite the PDB containing over 100 000
deposited X-ray crystal structures of proteins, only a small
number (3600 as of October 2016) are membrane proteins,
illustrating the difficulty in obtaining crystals of this important
class of proteins. Although new approaches have been
developed to improve this, with some success in the use of
crystallization techniques such as lipidic cubic phase, it still
proves a major challenge to reliably crystallize numerous
membrane-protein families (Caffrey, 2015). This lack of
structural information in turn limits the use of structure-based
drug design against a number of important membrane proteins
and thus hinders the development of potential therapeutics.
This is not just the case for membrane proteins; other potential
drug targets such as viruses and large protein complexes have
also proven to be difficult to crystallize for a variety of reasons,
including flexibility and size. When a structure is obtained
from crystallography there is also the possibility that some of
the observed interactions do not fully reflect the native state,
for example crystal-packing artefacts (Davis et al., 2003). A
further drawback in using crystal structures for structure-
based drug design is that they may only reflect a handful of
conformational states and not show the full dynamic range of
the system.
2. Advantages of electron microscopy
Electron microscopy (EM) overcomes many of the hurdles
and limitations experienced by crystallography. The first
advantage is that a typical single-particle EM experiment will
require microgram quantities of pure, homogenous protein,
rather than the milligram quantities often required to screen
for optimum crystallization conditions. The greatest advantage
of EM over X-ray crystallography is it negates the need for
well diffracting protein crystals, which can often create the
greatest bottleneck in the crystallography pipeline. This opens
up new avenues for the structural determination of previously
intractable targets, from large macromolecules such as viruses
to membrane proteins, where the presence of detergent makes
crystallization a challenge (Bill et al., 2011). EM also offers
potential advantages for drug discovery by being able to trap
different conformational states of a protein, moving away
from static crystal structures to a dynamic ensemble of
different states (Dashti et al., 2014; Frank & Ourmazd, 2016).
This could prove to be extremely powerful, as inhibitor-
binding pockets can display plasticity and change shape as the
protein samples different conformations. This dynamic range
is illustrated in EM studies on the vacuolar ATPase
(V-ATPase), which has been captured in three different
conformational states (Zhao et al., 2015). These states display
significant differences, with many subunits undergoing
conformational changes, for example during cycling between
states subunit C changes shape and exposes a charged
surface cleft (Fig. 1). This information is not seen in current
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crystallographic studies of the V-ATPase for a variety of
reasons. Firstly, the full complex is very large (1 MDa) and
flexible, which has made efforts to crystallize the full complex
impossible thus far. Secondly, in the absence of the full
complex and the interactions that it makes with other subunits
it is unlikely that the isolated C subunit would adopt the three
different states seen in EM, with only one state currently
solved by X-ray crystallography.
However, in the past EM has not been a viable technique
for structure-based drug design, primarily owing to the low
resolutions that were generally obtainable, leading to EM
being known as ‘blobology’. One methodology to identify
inhibitor-binding sites is through the use of tagging, which
significantly increases the mass of the inhibitor, making it
visible at nanometre resolution, but is limited to amenable
systems (Muench et al., 2014). While in the past EM has
achieved approximately nanometre resolution at best for most
samples, recent technological advances have now enabled
near-atomic resolutions to become obtainable (Fig. 2).
Improvements in microscope stability, and particularly the
development of direct electron detectors, have formed the
basis for the resurgence of EM as a mainstream structural
technique (Smith & Rubinstein, 2014; Glaeser, 2016; Nogales,
2016). Direct electron detectors have not only increased the
sensitivity and contrast of the images, but also allow the
capture of high-frame-rate movies. These movies, in conjunc-
tion with new processing algorithms, allow the motion of the
specimen during the exposure owing to both mechanical and
beam-induced movements to be accounted for, reducing the
blurring of the image and allowing higher resolution infor-
mation to be recovered. Moreover, the ability to remove the
later frames permits greater electron-dose exposures to be
conducted, which significantly improves the contrast. Those
frames which relate to the higher radiation dose can be
removed, which can mitigate one of the largest remaining
challenges in EM: radiation damage. With these improve-
ments allowing higher resolution structures to be obtained,
there have already been a number of structures published in
complex with ligands and inhibitors (Fig. 3), from large soluble
complexes such as the proteasome and -galactosidase to
smaller membrane proteins including TRP channels and
gamma secretase (Bartesaghi et al., 2014; Bai et al., 2015;
Paulsen et al., 2015; Gao et al., 2016; Li et al., 2016).
3. Challenges faced by electron microscopy
While EM offers many exciting new possibilities to play a role
in, and enhance, structure-based drug design, there are still
several significant challenges that hinder its widespread use.
Foremost amongst these obstacles is the limited resolution
that is currently obtainable. Despite the recent advances
detailed in this article, EM still lags behind X-ray crystallo-
graphy in that obtaining a sub-2.5 A˚ resolution for biological
specimens is far from routine. This is a severe limitation, as
details of the binding mode and precise interactions between
side chains, waters and the ligand are only observable at
higher resolutions. It is well established that EM can provide
atomic resolution structures in the materials field, and it is
routinely used for this. As such, the main factors hindering
resolution in biological EM are twofold: the radiation damage
sustained by the sample and the movement of the specimen
itself in the electron beam.
While X-ray crystallographic studies are also affected by
radiation damage, the problem is significantly worse for EM;
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Figure 1
The changing shape of a potential binding pocket in V-ATPase subunit C. Atomic surface representation of yeast V-ATPase subunit C in three states
showing binding-site plasticity as the complex proceeds through its catalytic cycle (PDB entries 3j9t, 3j9u and 3j9v; Zhao et al., 2015). The surface is
coloured by electrostatic potential, with red and blue representing negative and positive charge, respectively, showing a large positively charged cavity
being exposed in state 2. This cavity is not seen within the other states of the V-ATPase complex and may provide an opportunity to lock the catalytic
cycle within the second state.
indeed, it has been compared with a nuclear explosion at the
specimen scale (Glaeser & Taylor, 1978; Orlova & Saibil,
2011). As direct detectors allow the capture of movie frames,
this allows the use of all of the data, including later frames
from the exposure, to align the images, giving higher contrast
and easier alignment. A subset of these frames with lower
dose is then used to perform the reconstructions, reducing the
effects of radiation damage. However, it has been estimated
that a significant loss of high-resolution information occurs
after doses of around 3 e A˚2 (Baker et al., 2010; Vinoth-
kumar et al., 2014; Grant & Grigorieff, 2015), and much of this
dose occurs within the first moments of the exposure. More-
over, the frames which would contain this high-resolution
information suffer from the worst effects of beam-induced
motion, whereby movements occur as the grid is first exposed
to the electron beam through poorly understood combinations
of charging and expansion/contraction of the vitreous ice and
the support film, which is typically made of amorphous carbon
(Brilot et al., 2012; Glaser et al. 2011). This means that with
current methodology these frames cannot be used, making
extremely high resolution (1 A˚) structures unlikely in the
near future, although research into new support substrates
which may limit the problems associated with grid expansion
and improve stability is ongoing (Russo & Passmore, 2014,
2016). Radiation damage can also have a more subtle effect
aside from the degradation of resolution, where damage
causes protein side chains to shift, which could lead to subtle
differences in the inhibitor binding position. Previous studies
have shown that negative side chains appear to suffer radia-
tion damage preferentially (Allegretti et al., 2014; Bartesaghi
et al., 2014; Grant & Grigorieff, 2015), so if there are key
negatively charged residues in the binding pocket then this
may induce a significant movement of the inhibitor or show a
binding mode which is not physiologically relevant. However,
it should be noted that weak density for negative side chains
can also be a feature of the electric potential map generated in
the electron-microscopy experiment (Wang & Moore, 2017)
and is not in all cases radiation damage.
While EM can tackle proteins that are intractable for crystal
studies, such as large complexes and membrane proteins, the
current limitations in technology impose a size limit on the
proteins that can be observed. Currently, proteins smaller than
200 kDa prove a major challenge for EM, although there are
exceptions to this (Merk et al., 2016). While developments are
under way to improve this, and while there has already been
significant progress through the use of direct detectors, this
size limitation still hinders the use of EM for several important
classes of drug targets, including GPCRs. As such, this is the
subject of much ongoing research, particularly the develop-
ment of phase plates (discussed in more detail below).
A further drawback of using an EM approach for structure-
based drug-design purposes is the speed at which structures
can be obtained. While in crystallography it is routine to set up
several co-crystallizations or soaks simultaneously and the
data collection for each crystal obtained is very rapid
(minutes), EM data collection is still relatively slow, typically
taking several days of collection for a single sample. This is
particularly an issue for fragment-based discovery: whereas
crystallography programs such as XChem, developed at the
Diamond Light Source (UK), are capable of screening up to
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Figure 2
Example EM density showing bound ligands. (a) Resiniferatoxin ligand density from TRPV1 at 2.95 A˚ resolution (EMDB entry 8117, PDB entry 5irx;
Gao et al., 2016). (b) 3.6 A˚ resolution proteasome EM density showing bound inhibitor (EMBD entry 3231, PDB entry 5fmg; Li et al., 2016). For both
panels the EM density map is shown in mesh format and side chains and bound inhibitor are shown in stick format and are coloured light blue, dark blue,
red and yellow for carbon, nitrogen, oxygen and sulfur, respectively.
500 crystals in a single day for bound fragments, this scale of
throughput is not yet possible for EM studies. The primary
reason for this is the typical requirement for over 100 000
‘particles’, which in the absence of symmetry can require in
excess of 2000 micrographs. This level of data can be achieved
within 2–3 days of microscope time using automatic data-
collection runs on the microscope. Processing of the resulting
data can also take significant time, of the order of weeks to
months to extract the most from the raw data, currently
precluding EM as a high-throughput structural technique.
Tied to this is the volume of data that is produced in a single
EM experiment, with a single micrograph being between 1 and
10 GB in size, leading to data sets of >10 TB for a single
specimen. This presents a major infrastructure challenge, and
makes the initial barrier to entry for EM substantial without
significant resources dedicated to processing and data storage.
Nevertheless, improvements are being made in the speed of
data acquisition and enhancing the speed of image processing.
Fragment-based screening is particularly challenging for EM
owing to issues of low occupancy, as a large number of indi-
vidual molecules need to be averaged to obtain high-
resolution reconstructions, and thus inhibitor density will be
lost with partial occupancy. This may be overcome to some
extent if the binding of the fragment induces a large confor-
mational change that could be identified through classification
of the data set such that ‘bound’ and ‘unbound’ can be
computationally sorted. However, unlike crystallographic
studies, the ability to raise the ligand concentration signifi-
cantly above the Kd, for example through crystal soaking,
becomes challenging, especially for peptide inhibitors, where a
large excess will result in significant reductions in contrast
within the cryo-EM image.
4. Future potential
EM has a promising role to play in structure-based drug-
design approaches, despite the current challenges that need to
be addressed. One of the key limitations that EM must over-
come in order to hold widespread appeal in drug development
is the size limitation of the proteins that can be studied. This
limitation is based around the low signal-to-noise ratio (SNR)
and the low contrast of biological samples in EM at typical
dose ranges (20 e A˚2). The increased SNR from the
advent of direct detectors has already allowed a decrease in
the minimum molecular weight from 500 to 150–200 kDa.
Further increases in contrast and the SNR can be gained
through phase-plate technology, which is under development
by several groups and companies, with the Volta phase plate
already allowing the structures of human Prx3 (250 kDa)
and the nucleosome core particle to be determined (Chua et
al., 2016; Khoshouei et al., 2016). Both phase plates and direct
detectors are still in their infancy; with further development
and optimization this technology could enable EM to look at a
much wider range of proteins than are currently viable.
Another method in development to increase the range of
viable proteins for study via EM is through the use of affinity
grids. Structural studies of several potentially therapeutically
interesting proteins are precluded simply by difficulties in
obtaining sufficiently pure protein to carry out EM studies.
This can be owing to challenges in generating sufficient yields
because of difficulty in overexpressing functional protein
owing to factors such as cell toxicity, poor folding, recycling
and expense in large-volume expression, especially with HEK
cells. To combat this, rather than performing traditional large-
scale overexpression and purification and studying the
resulting protein via EM, work is ongoing to purify the sample
directly onto the EM grid (Benjamin et al., 2016; Yu et al.,
2016). Various methods are being developed to achieve this,
from immobilizing antibodies to the grid surface to tethering
the protein of interest to the grid (requiring no prior genetic
manipulation) or alternatively applying nickel-doped lipid
monolayers to the grid surface to extract His-tagged protein
directly. While currently the only examples of this work at high
resolution have been highly symmetrical virus structures, with
further development it could become a powerful technique for
the structural study of hard-to-obtain proteins (Yu et al.,
2016).
General advances in microscopes, including the use of
spherical aberration (Cs) correction, which has already been
shown to aid in obtaining high-resolution structural informa-
tion (Fischer et al., 2015), and detectors should enable further
increases in resolution, allowing more valuable information
about ligand binding to be extracted from the resulting
reconstructions. In addition to this, computational power is
constantly increasing, meaning that the computational
bottlenecks that currently hinder the rapid processing of EM
data should lessen over time. At the same time, graphical
acceleration of the processing pipeline using GPU technology
is an active area of research, with several key steps already
having been optimized in this manner, cutting processing
times for these steps from days to hours (Zhang, 2016).
Further work is ongoing in utilizing this dramatic acceleration
to speed up the currently slow steps of classification and
refinement. With the rapid rate of change in computational
power and developments such as GPU acceleration, it is easy
to envisage a processing pipeline for EM where several
processing steps are carried out ‘on the fly’ as data are
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Figure 3
Single-particle EM resolution trends from 2005 to 2016: the change in the
average (black) and highest (grey) resolution of structures determined by
single-particle EM deposited in the EMDB from 2005 to 2016.
collected, in an analogous manner to X-ray data collection at
many synchrotron sources (Lander et al., 2009; la Rosa-Trevı´n
et al., 2016).
Advances in technology and computation may also allow
EM to study biological processes in a time-dependent manner,
giving insight into the dynamic changes that occur within the
system. Work is ongoing to develop time-resolved EM through
a variety of methods, including rapid mixing/spraying in order
to physically trap the protein of interest in a variety of func-
tional states (Walker et al., 1995; Lu et al., 2009; Chen & Frank,
2016), as well as computational manifold mapping approaches,
which have already been utilized to identify several functional
conformational states of the ribosome (Dashti et al., 2014;
Frank & Ourmazd, 2016). By removing the constraints of a
crystal lattice, it is possible to map the larger conformational
changes associated with catalytic cycling, which is invaluable
in understanding the full dynamic range of a protein–protein
complex. Only by moving away from ‘static’ snapshots can we
fully understand the plasticity of inhibitor-binding pockets and
identify new binding sites.
For membrane proteins, a significant challenge, especially
for structure-based inhibitor design, is to study the protein in a
more native state that better reflects the target structure. New
methodologies for extracting membrane proteins in more
native states have been reported, for example styrene maleic
acid lipid particles (SMALPs), which extract membrane
proteins with their native lipids rather than in detergent
micelles, and have been used for EM analysis (Postis et al.,
2015; Lee et al., 2016). Furthermore, saposonin–lipoprotein
nanoparticles have shown promise in high-resolution cryo-EM
studies on membrane proteins (Frauenfeld et al., 2016).
Nanodiscs also offer the potential to create more native
environments that can be adapted for different lipid envir-
onments (Gao et al., 2016). However, there is a limitation with
all of these technologies in that they all represent an ‘open’
system whereby a chemical gradient or membrane potential
cannot be generated. This is particularly pertinent for ion
channels and transporters, where the native conformational
state cannot be seen in the absence of such a gradient. This
provides a challenge for structure-guided inhibitor design
where the structure of the conformational state which
predominates in the natural system is not seen. To overcome
these challenges it is beneficial to reconstitute the membrane
protein within a proteoliposome, which can maintain such a
gradient. The use of this approach has been used to investigate
the BK channel and mouse serotonin 5-HT3 (Wang &
Sigworth, 2009; Kudryashev et al., 2016), and with improved
data-collection speeds and processing approaches this could
become a powerful means of studying membrane proteins in
more ‘native’ environments, better reflecting the different
conformational states that are accessible.
5. Concluding remarks
Although the use of EM as a tool for structure-based drug
design is in its infancy and has not yet been reported to
actively design new lead compounds, it is clear that it offers a
wide range of new opportunities. While the resolution of EM
is constantly increasing and new technological developments
will only accelerate this, it is likely that X-ray crystallography
will remain the gold-standard technique for atomic resolution
information in the near future. However, EM can provide a
wealth of potentially valuable complementary information,
including insight into conformational dynamics and, crucially,
high-resolution structural information from a more native
state freed from the constraints of the crystal lattice.
This could provide a vital contribution to the drug-design
pipeline through both target-validation and structure-guided
approaches.
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